- Published at
- by manilatimes.net
mixed
mixed
News for Arena Pharmaceuticals, Inc. (ARNA)
- Published at
- by gurufocus.com
mixedmixedInhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth
-- Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- Amit Munshi Appointed Chai- Published at
- by globenewswire.com
mixedmixedAtossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development
Dr. Lopez Brings 20+ Years of Global Clinical Development and Leadership to Support Atossa’s Mission in Developing Innovative Breast Cancer Therapies...- Published at
- by manilatimes.net
mixedmixed- Published at
- by globenewswire.com
mixedmixedInhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension
-- IkT-001Pro to be developed as a New Molecular Entity as the first oral, potentially disease-modifying treatment for a rapidly fatal disease primarily...- Published at
- by insidermonkey.com
positivepositive- Published at
- by investing.com
mixedmixedVentyx Biosciences appoints new interim finance chiefs By Investing.com
Ventyx Biosciences appoints new interim finance chiefs- Published at
- by investing.com
mixedmixedPepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development By Investing.com
PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development- Published at
- by investing.com
mixedmixedHow Cannabinoid Biotechs Are Potentially Enhancing Long-Term Stock Performance
Stocks Analysis by Joel Latham covering: Eli Lilly and Company, Pfizer Inc, Redhill Biopharma Ltd, Corbus Pharmaceuticals Holding. Read Joel Latham's latest article on Investing.com- Published at
- by globenewswire.com
mixedmixedSagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
SAN MATEO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company...- Published at
- by globenewswire.com
positivepositiveAbivax Provides Operational and Key Program Update
Abivax Provides Operational and Key Program Update Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC)...- Published at
- by finance.yahoo.com
mixedmixedDown 55%, Is Pfizer a Good Dividend Stock to Buy on the Dip?
Shares of the world's largest drugmaker offer a dividend yield above 6% at recent prices.- Published at
- by globenewswire.com
neutralneutralAnavex Life Sciences Announces Expansion of Leadership Team
Strengthening Operational Efficiency and Execution towards Sustainable Accessibility for Diverse Populations within Global Healthcare Systems...- Published at
- by investing.com
mixedmixedConnect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update By Investing.com
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update- Published at
- by gurufocus.com
neutralneutralPfizer Inc Analyst and Investor Call to Discuss Etrasimod Data Presentation at Digestive Disease Week Call Transcript
May 24, 2022 / 08:00PM GMTPresentation at Digestive Disease Week CallMay 24, 2022 / 08:00PM GMT =====================Corporate Participants=====================- Published at
- by seekingalpha.com
positivepositiveBehind The Huge Rally In Longboard Pharmaceuticals (NASDAQ:LBPH)
Longboard Pharmaceuticals, Inc. shares have surged in 2024 due to positive mid-stage trial data. Click here for more on the LBPH stock prospects.- Published at
- by globenewswire.com
positivepositiveAvalo Therapeutics Announces 1-for-240 Reverse Stock Split
WAYNE, Pa. and ROCKVILLE, Md., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced a 1-for-240 reverse stock split...- Published at
- by seekingalpha.com
positivepositiveMoonLake Immunotherapeutics: Time To Hit Pause After Miraculous Gains (NASDAQ:MLTX)
MoonLake stock has seen a 400% increase in value since its listing on the Nasdaq, and has raised over $450 million through equity offerings. Read more here.- Published at
- by businesstoday.in
mixedmixedIndian pharma cos speed up anti-obesity drug development amid high demand, surge in Ozempic’s sales
Sun Pharma, Dr. Reddy's, Lupin, Torrent, and Zydus Cadila progressing obesity drug candidates in response to rising demand. Notable developments include Sun Pharma's Phase 1 studies and Dr. Reddy’s Laboratories' permission for a semaglutide bioequivalence study- Published at
- by thepost.on.ca
mixedmixedCOVID-19 vaccine winners suffer reversal of fortune
Pharma companies have yet to provide investors with convincing post-pandemic strategies. Read more.